Vivos Therapeutics Reports 35% Revenue Growth to $5.2 Million, Faces Increased Net Loss

Vivos Therapeutics, Inc. reported a total revenue of $5.2 million for the three months ended June 30, 2026, marking a 35% increase from $3.8 million in the same period last year. The growth was primarily driven by a significant rise in service revenue, which increased by approximately $1.9 million, while product revenue saw a decline of about $0.5 million. For the six months ended June 30, 2026, total revenue reached $10.3 million, a 51% increase compared to $6.8 million in the prior year. This increase was largely attributed to a $4.4 million rise in service revenue, particularly from sleep testing services associated with the company's acquisition of The Sleep Center of Nevada (SCN) in June 2025.

Despite the revenue growth, Vivos reported a net loss of $5.5 million for the second quarter of 2026, slightly higher than the $5.0 million loss recorded in the same quarter of 2025. For the first half of 2026, the net loss was $13.3 million, compared to $8.9 million in the previous year. The increase in losses was attributed to higher general and administrative expenses, which rose by approximately $4.8 million due to costs associated with the SCN acquisition and the establishment of new treatment centers. Operating expenses for the second quarter totaled $7.8 million, up from $7.0 million in the prior year.

In terms of operational developments, Vivos has shifted its business model to focus on strategic alliances and acquisitions of sleep centers, moving away from its previous reliance on dental practices for revenue generation. The acquisition of SCN has allowed the company to capture diagnostic and consulting revenues, which are expected to provide higher margins. As of June 30, 2026, Vivos had approximately 75,000 patients treated worldwide and over 2,000 trained dentists utilizing its products. The company is also exploring additional acquisitions to further expand its market presence.

Vivos's financial position remains precarious, with total liabilities of approximately $28.1 million as of June 30, 2026, and cash and cash equivalents of only $1.8 million, insufficient to fund operations for the next twelve months. The company has indicated that it will need to secure additional financing to continue operations and meet Nasdaq compliance requirements, as its stockholders' equity was reported at a negative $3.8 million. The company has engaged in various financing activities, including a recent private placement that raised approximately $2.1 million, but it remains uncertain whether it can achieve the necessary capital to stabilize its financial situation.

Looking ahead, Vivos aims to increase revenues through its new medical provider-focused model and is optimistic about the potential for growth stemming from the SCN acquisition. However, the company acknowledges the risks associated with its ability to raise sufficient capital and generate positive cash flows. Management is actively reviewing options to secure additional funding and is focused on enhancing revenue through strategic partnerships and acquisitions in the healthcare sector.